JP6054371B2 - 病原性疾患における細菌ｍａｍポリペプチドの調節 - Google Patents

病原性疾患における細菌ｍａｍポリペプチドの調節 Download PDF

Info

Publication number
JP6054371B2
JP6054371B2 JP2014503699A JP2014503699A JP6054371B2 JP 6054371 B2 JP6054371 B2 JP 6054371B2 JP 2014503699 A JP2014503699 A JP 2014503699A JP 2014503699 A JP2014503699 A JP 2014503699A JP 6054371 B2 JP6054371 B2 JP 6054371B2
Authority
JP
Japan
Prior art keywords
mam7
mam
infection
cells
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014503699A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014512361A (ja
JP2014512361A5 (enExample
Inventor
キム オルト
キム オルト
ハイエイリン ハム
ハイエイリン ハム
アン マリー クラハラー
アン マリー クラハラー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2014512361A publication Critical patent/JP2014512361A/ja
Publication of JP2014512361A5 publication Critical patent/JP2014512361A5/ja
Application granted granted Critical
Publication of JP6054371B2 publication Critical patent/JP6054371B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
JP2014503699A 2011-04-06 2012-03-30 病原性疾患における細菌ｍａｍポリペプチドの調節 Expired - Fee Related JP6054371B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472440P 2011-04-06 2011-04-06
US61/472,440 2011-04-06
PCT/US2012/031552 WO2012138570A2 (en) 2011-04-06 2012-03-30 Modulating bacterial mam polypeptides in pathogenic disease

Publications (3)

Publication Number Publication Date
JP2014512361A JP2014512361A (ja) 2014-05-22
JP2014512361A5 JP2014512361A5 (enExample) 2015-05-21
JP6054371B2 true JP6054371B2 (ja) 2016-12-27

Family

ID=46969760

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014503699A Expired - Fee Related JP6054371B2 (ja) 2011-04-06 2012-03-30 病原性疾患における細菌ｍａｍポリペプチドの調節

Country Status (6)

Country Link
US (2) US9140698B2 (enExample)
EP (1) EP2693887B1 (enExample)
JP (1) JP6054371B2 (enExample)
AU (1) AU2012240395B2 (enExample)
CA (1) CA2832443C (enExample)
WO (1) WO2012138570A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9901616B2 (en) 2011-08-31 2018-02-27 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
US10416167B2 (en) 2012-02-17 2019-09-17 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
EP2833911A4 (en) 2012-04-06 2016-07-13 Univ Cornell SUB-VACCINE VACCINATING PLATFORM FOR ROBUST HUMORAL AND CELLULAR IMMUNE RESPONSES
US9815871B2 (en) 2013-04-23 2017-11-14 President And Fellows Of Harvard College Genetic reprogramming of bacterial biofilms
EP3039733B1 (en) * 2013-08-29 2018-11-21 Northeastern University Matrix-enhanced electrochemical detector for pathogenic bacteria
US10398663B2 (en) 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
JP6916524B2 (ja) 2015-04-06 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 機能的タンパク質配列をディスプレイする生合成アミロイドに基づく材料
US11098133B2 (en) 2016-05-19 2021-08-24 President And Fellows Of Harvard College Methods of making gels and films using curli nanofibers
CA3214423A1 (en) * 2017-02-17 2018-08-23 The University Of British Columbia Probiotic compositions and uses thereof
EP3720458A4 (en) 2017-12-05 2021-12-08 BioPlx, Inc. METHODS AND COMPOSITIONS FOR PREVENTING MICROBIAL INFECTION
GB202003062D0 (en) 2020-03-03 2020-04-15 Univ Sheffield Antimicrobial target
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN111848734B (zh) * 2020-06-17 2022-04-05 自然资源部第三海洋研究所 一种具有荧光特性的铁载体pvd、制备方法及其用途
CN112007143B (zh) * 2020-08-19 2023-09-22 中山大学 重组副溶血弧菌鞭毛蛋白在提高鱼类免疫力中的应用
WO2024059139A2 (en) * 2022-09-13 2024-03-21 University Of Cincinnati Engineered probiotics expressing anti-inflammatory molecules

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE69126607T2 (de) 1990-01-23 1998-01-15 Tanox Biosystems, Inc., Houston, Tex. Extrazelluläre teilstücke humaner ige-immunoglobulin-ankerpeptide und dafür spezifische antikörper
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
AU1570292A (en) 1991-02-07 1992-09-07 Board Of Trustees Of The University Of Illinois, The Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
US5475085A (en) 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5840833A (en) 1995-10-27 1998-11-24 Molecumetics, Ltd Alpha-helix mimetics and methods relating thereto
US5929237A (en) 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US6444444B1 (en) * 1996-07-10 2002-09-03 Aventis Pasteur Limited Genes encoding mycobacterial proteins associated with cell binding and cell entry and uses thereof
US6284255B1 (en) 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US7666400B2 (en) 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US7223558B2 (en) * 2001-07-11 2007-05-29 Bristol-Myers Squibb Company Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunologobulin folds, BGS2, 3, and 4 and variants thereof
US20030138490A1 (en) 2001-09-08 2003-07-24 Zhibing Hu Synthesis and uses of polymer gel nanoparticle networks
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
WO2004089421A2 (en) 2003-03-31 2004-10-21 Xencor, Inc Methods for rational pegylation of proteins
JP2007530034A (ja) * 2004-03-23 2007-11-01 エヌ．ブイ．・ヌートリシア 新規のマンノース特異的アドヘシンとその使用
GB0423126D0 (en) * 2004-10-18 2004-11-17 Ares Trading Sa Protein
US20090048160A1 (en) * 2007-08-17 2009-02-19 Bannerman Douglas D Antimicrobial activity of bovine bactericidal/permeability-increasing protein (BPI)-derived peptides against Gram-negative bacterial mastitis isolates
US8110656B2 (en) * 2008-07-22 2012-02-07 Board Of Trustees Of Michigan State University Compositions and methods of a phosphatidic acid binding protein

Also Published As

Publication number Publication date
CA2832443C (en) 2020-08-25
AU2012240395A1 (en) 2013-10-24
AU2012240395B2 (en) 2016-02-04
US20140093477A1 (en) 2014-04-03
US9529005B2 (en) 2016-12-27
EP2693887A2 (en) 2014-02-12
WO2012138570A3 (en) 2012-11-29
WO2012138570A2 (en) 2012-10-11
EP2693887A4 (en) 2015-04-08
JP2014512361A (ja) 2014-05-22
US9140698B2 (en) 2015-09-22
EP2693887B1 (en) 2020-10-28
US20160169921A1 (en) 2016-06-16
CA2832443A1 (en) 2012-10-11

Similar Documents

Publication Publication Date Title
JP6054371B2 (ja) 病原性疾患における細菌ｍａｍポリペプチドの調節
Kemper et al. Campylobacter jejuni: targeting host cells, adhesion, invasion, and survival
Smith et al. Extraintestinal pathogenic Escherichia coli
Totsika et al. Uropathogenic Escherichia coli mediated urinary tract infection
Kampmeier et al. The 2011 German enterohemorrhagic Escherichia coli O104: H4 outbreak—The danger is still out there
Fowler et al. Emerging insights into the biology of typhoid toxin
US20170145061A1 (en) Engineered bacteroides outer membrane vesicles
Gao et al. Emerging of a highly pathogenic and multi-drug resistant strain of Escherichia coli causing an outbreak of colibacillosis in chickens
Tischler et al. Contrasting persistence strategies in Salmonella and Mycobacterium
CN107073073B (zh) 经肺施用绿脓菌素用于治疗细菌性呼吸道感染
WO2017044989A1 (en) Clostridium difficile BACTERIOPHAGE LYSINS FOR DETECTION AND TREATMENT OF Clostridium difficile BACTERIA INFECTION
CN115942953A (zh) 用于治疗菌群失调的atp水解酶
Safarpour-Dehkordi et al. A comprehensive investigation of the medicinal efficacy of antimicrobial fusion peptides expressed in probiotic bacteria for the treatment of pan drug-resistant (PDR) infections
US20250236648A1 (en) Constitutive production of microcins to target enteric bacteria
Laura et al. E. coli alpha hemolysin and properties
Zgheib Contribution of alginate nanoparticles to the multifunction of antimicrobial peptides, example of the class IIb bacteriocin Enterocin DD14
JP2022545085A (ja) ガイド抗菌ペプチドのプロバイオティクス送達
WO2014102694A1 (en) Novel mucinase for use in therapy or prophylaxis
Zhang et al. The pulmonary commensal Lactobacillus regulated lung γδ T cells to enhance resistance against bacterial infections
Pellegrini The global transcriptional regulator CodY controls virulence in Group B Streptococcus
Maurizi Interplay between uropathogenic Escherichia coli and bladder cells and new strategies to counteract bacterial persistence
Sabnis Colistin: understanding the mechanism of action and the causes of treatment failure
Schnizlein Examining Regional Differences in the Gut Microbiota and Their Effects on Clostridioides difficile Colonization Resistance
Sinha PmrC and CptA-mediated regulation of outer membrane vesicle production in Citrobacter rodentium
Bavro Lipid A: Rationale for Drug Targeting

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150330

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160607

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161130

R150 Certificate of patent or registration of utility model

Ref document number: 6054371

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees